

DAFTAR PUSTAKA

- Agraval, H. and Chu, H.W., 2022. Lung Organoids in Smoking Research: Current Advances and Future Promises. *Biomolecules*, 12(10), p.1463.
- Agur, A.M. and Dalley, A.F., 2023. *Moore's essential clinical anatomy*. Lippincott Williams & Wilkins.
- American Cancer Society (ACS), 2024. Lung Cancer Early Detection, Diagnosis, and Staging. The American Cancer Society medical and editorial content team.
- Anggaraditya, P.B., Adiputra, P.A.T. and Widiani, I.K., 2019. EGFR nanovaccine in lung cancer treatment. *Bali Medical Journal*, 8(3), pp.844-851.
- Barrett K, Barman S, Brooks H, Yuan J. 2019. Ganong's Review of Medical Physiology. 26th Ed. United State: McGraw-Hill Education
- Bi, H., Yin, L., Fang, W., Song, S., Wu, S. and Shen, J., 2023. Association of CEA, NSE, CYFRA 21-1, SCC-Ag, and ProGRP with clinicopathological characteristics and chemotherapeutic outcomes of lung cancer. *Laboratory Medicine*, 54(4), pp.372-379.
- Blechter, B., Wong, J.Y., Chien, L.H., Shiraiishi, K., Shu, X.O., Cai, Q., Zheng, W., Ji, B.T., Hu, W., Rahman, M.L. and Jiang, H.F., 2024. Age at lung cancer diagnosis in females versus males who never smoke by race and ethnicity. *British Journal of Cancer*, 130(8), pp.1286-1294.
- Budisan, L., Zanoaga, O., Braicu, C., Pirlog, R., Covaliu, B., Esanu, V., Korban, S.S. and Berindan-Neagoe, I., 2021. Links between infections, lung cancer, and the immune system. *International journal of molecular sciences*, 22(17), p.9394.
- Chen, H., Fu, F., Zhao, Y., Wu, H., Hu, H., Sun, Y., Zhang, Y., Xiang, J. and Zhang, Y., 2021. The prognostic value of preoperative serum tumor markers in non-small cell lung cancer varies with radiological features and histological types. *Frontiers in Oncology*, 11, p.645159.
- Chen, P., Liu, Y., Wen, Y. and Zhou, C., 2022. Non-small cell lung cancer in China. *Cancer Communications*, 42(10), pp.937-970.
- Chen, S., Kuang, M., Wang, S., Huang, S., Li, J., Zhou, T., Wang, H., Cai, Y., Yang, W. and Xie, Q., 2022. Diagnostic and Prognostic Significance of Serum Tumor Markers in Patients With Lung Cancer.
- Chen, T., Zhou, F., Jiang, W., Mao, R., Zheng, H., Qin, L. and Chen, C., 2019. Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients. *Journal of Thoracic Disease*, 11(6), p.2251.
- Chen, Z.Q., Huang, L.S. and Zhu, B., 2018. Assessment of seven clinical tumor markers in diagnosis of non-small-cell lung cancer. *Disease Markers*, 2018(1), p.9845123.
- Dahlan, M Sopiyyudin, 2018. Penelitian Diagnostik, Validitas & Reliabilitas Dasar-Dasar Teoretis dan Aplikasi Dengan Program SPSS dan Stata. Edisi 2. PT Epidemiologi Indonesia.
- Detterbeck, F.C., 2018. The eighth edition TNM stage classification for lung cancer: What does it mean on main street?. *The Journal of thoracic and cardiovascular surgery*, 155(1), pp.356-359.
- Dhanurdhar, Y., Jagaty, S.K., Subhankar, S. and Behera, D., 2023. Diagnostic and Prognostic Significance of Serum Biomarkers—Serum Amyloid A and

- CYFRA 21-1 in Lung Cancer. *International Journal of Applied and Basic Medical Research*, 13(2), pp.89-94.
- DiGiacomo, S.I., Jazayeri, M.A., Barua, R.S. and Ambrose, J.A., 2019. Environmental tobacco smoke and cardiovascular disease. *International journal of environmental research and public health*, 16(1), p.96.
- Dou, X., Lu, J., Yu, Y., Yi, Y. and Zhou, L., 2024. Determination of Tumor Marker Screening for Lung Cancer Using ROC Curves. *Disease Markers*, 2024(1), p.4782618
- Drake, R.L., Vogl, A.W., Mitchell, A.W., Tibbitts, R. and Richardson, P., 2020. *Gray's Atlas of Anatomy E-Book: Gray's Atlas of Anatomy E-Book*. Elsevier Health Sciences.
- Elecsys, 2023. Elecsys CYFRA 21-1 in Standard Operating Procedure. Roche Diagnostic GmbH, Mannheim. P: 1-5
- Fu, L., Wang, R., Yin, L., Shang, X., Zhang, R. and Zhang, P., 2019. CYFRA21-1 tests in the diagnosis of non-small cell lung cancer: a meta-analysis. *The International journal of biological markers*, 34(3), pp.251-261.
- Garcia-Valdecasas Gayo, S., Ruiz-Alvarez, M.J., Gonzalez-Gay, D., Ramos-Corral, R., Marquez-Lietor, E., Del Amo, N., Plata, M.D.C., Guillén-Santos, R., Arribas, I. and Cava-Valenciano, F., 2020. CYFRA 21-1 in patients with suspected cancer: evaluation of an optimal cutoff to assess the diagnostic efficacy and prognostic value. *Advances in Laboratory Medicine/Avances en Medicina de Laboratorio*, 1(4), p.20200005
- Gee, K. and Yendamuri, S., 2024. Lung cancer in females—sex-based differences from males in epidemiology, biology, and outcomes: a narrative review. *Translational Lung Cancer Research*, 13(1), p.163.
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: a cancer journal for clinicians*, 71(3), pp. 209-249.
- Grippi, M.A., Ozerkis D.E., Cruz C.S., Kotloff R., Kotloff C, Pac A.I., 2022. *Fishman's Pulmonary Diseases and Disorders, 2-Volume Set* 6th edition. McGraw Hill Professional.
- Gutic, B., Bozanovic, T., Mandic, A., Dugalic, S., Todorovic, J., Stanisavljevic, D., Dugalic, M.G., Sengul, D., Detanac, D.A., Sengul, I. and Detanac, D., 2023. Programmed cell death-1 and its ligands: current knowledge and possibilities in immunotherapy. *Clinics*, 78, p.100177.
- Hana, J. and Faizah, N.N., 2023. Diagnostic Approach of Lung Cancer: A Literature. *Lung cancer*.
- Huang, J., Xiao, Y., Zhou, Y., Deng, H., Yuan, Z., Dong, L., Lan, J., Li, X., Liu, G., Hu, H. and Huang, S., 2023. Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study. *BMC cancer*, 23(1), p.812.
- Izawa, A., Hara, Y., Horita, N., Muraoka, S., Kaneko, M., Kaneko, A., Somekawa, K., Hirata, M., Otsu, Y., Matsumoto, H. and Nagasawa, R., 2024. Improved diagnostic accuracy with three lung tumor markers compared to six-marker panel. *Translational Lung Cancer Research*, 13(3), p.503.

- Jiang, Z.F., Wang, M. and Xu, J.L., 2018. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. *Life sciences*, 194, pp.1-6.
- Johnson, M., Garassino, M.C., Mok, T. and Mitsudomi, T., 2022. Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies. *Lung Cancer*, 170, pp.41-51.
- Kemenkes, 2023. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Paru
- Kloecker G, Arnold Susane, Fraig M, Perez, 2021. Lung cancer (Ebook)
- Kuburich, N.A., den Hollander, P., Pietz, J.T. and Mani, S.A., 2022, November. Vimentin and cytokeratin: Good alone, bad together. In *Seminars in cancer biology* (Vol. 86, pp. 816-826). Academic Press.
- Li, C., Lei, S., Ding, L., Xu, Y., Wu, X., Wang, H., Zhang, Z., Gao, T., Zhang, Y. and Li, L., 2023. Global burden and trends of lung cancer incidence and mortality. *Chinese Medical Journal*, 136(13), pp.1583-1590
- Li, J., Xu, H.L., Yao, B.D., Li, W.X., Fang, H., Xu, D.L. and Zhang, Z.F., 2020. Environmental tobacco smoke and cancer risk, a prospective cohort study in a Chinese population. *Environmental Research*, 191, p.110015.
- Marmor, H.N., Zorn, J.T., Deppen, S.A., Massion, P.P. and Grogan, E.L., 2023. Biomarkers in lung cancer screening: a narrative review. *Current challenges in thoracic surgery*, 5.
- Miao, Q., Cai, B., Niu, Q. and Zhang, J., 2022. Changes in lung cancer-related serum tumor markers in patients with chronic kidney disease and determination of upper reference limit. *Frontiers in Oncology*, 12, p.1072531.
- Minamibata, A., Kono, Y., Arimoto, T., Marunaka, Y. and Takayama, K., 2023. Variability of serum CYFRA 21– 1 and its susceptibility to clinical characteristics in individuals without cancer: a 4-year retrospective analysis. *BMC Pulmonary Medicine*, 23(1), p.344.
- Mohrherr, J., Uras, I.Z., Moll, H.P. and Casanova, E., 2020. STAT3: versatile functions in non-small cell lung cancer. *Cancers*, 12(5), p.1107.
- Montero, P., Milara, J., Roger, I. and Cortijo, J., 2021. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. *International journal of molecular sciences*, 22(12), p.6211.
- Muley, T., Herth, F.J., Heussel, C.P., Kriegsmann, M., Michael, T., Meister, M., Schneider, M.A., Wehnl, B., Mang, A. and Holdenrieder, S., 2023. Prognostic value of tumor markers ProGRP, NSE and CYFRA 21-1 in patients with small cell lung cancer and chemotherapy-induced remission. *Tumor Biology*, (Preprint), pp.1-14.
- Nicholson, A.G., Tsao, M.S., Beasley, M.B., Borczuk, A.C., Brambilla, E., Cooper, W.A., Dacic, S., Jain, D., Kerr, K.M., Lantuejoul, S. and Noguchi, M., 2022. The 2021 WHO classification of lung tumors: impact of advances since 2015. *Journal of Thoracic Oncology*, 17(3), pp.362-387.
- Nooraldeen, R. and Bach, H., 2021. Current and future development in lung cancer diagnosis. *International journal of molecular sciences*, 22(16), p.8661.

- Parris, B.A., O'Farrell, H.E., Fong, K.M. and Yang, I.A., 2019. Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. *Journal of thoracic disease*, 11(Suppl 17), p.S2155.
- Peng, D., Fu, M., Wang, M., Wei, Y. and Wei, X., 2022. Targeting TGF- β signal transduction for fibrosis and cancer therapy. *Molecular cancer*, 21(1), p.104.
- Pertiwi, W. and Sunaryo, M.Y., 2019. Evaluasi dan Follow Up Nodul Paru Soliter. *Jurnal Respirasi (JR)*, 5(3), pp.85-90.
- Pietrzak, J., Szmajda-Krygier, D., Wosiak, A., Świechowski, R., Michalska, K., Mirowski, M., Żebrowska-Nawrocka, M., Łochowski, M. and Balcerczak, E., 2022. Changes in the expression of membrane type-matrix metalloproteinases genes (MMP14, MMP15, MMP16, MMP24) during treatment and their potential impact on the survival of patients with non-small cell lung cancer (NSCLC). *Biomedicine & Pharmacotherapy*, 146, p.112559.
- Premnath, S.M. and Zubair, M., 2023. Electrochemiluminescence Method. In *StatPearls [Internet]*. StatPearls Publishing.
- Roche, 2023. Cobas Elecsys CYFRA 21-1 and Precicontrol. Roche Diagnostics.
- Sabbula, B.R., Gasalberti, D.P. and Anjum, F., 2023. Squamous cell lung cancer. In *StatPearls [Internet]*. StatPearls Publishing.
- Said, A.F., Abd, E.A., Mohamed, B.I., Ewis, A.A. and Mohammed, H.Y., 2015. Prognostic value of CYFRA 21-1 and carcinoembryonic antigen in non-small cell lung cancer. *Journal of Clinical and Cellular Immunology*, 6(02).
- Saladin & Gan, 2023. Anatomy & physiology the unity of form and function kenneth s. saladin. McGraw Hill.
- Saller, J.J. and Boyle, T.A., 2021. Molecular pathology of lung cancer. *Cold Spring Harbor Perspectives in Medicine*, p.a037812.
- Sharma, P., Alsharif, S., Fallatah, A. and Chung, B.M., 2019. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin. *Cells*, 8(5), p.497.
- Shi, T., Zhu, S., Guo, H., Li, X., Zhao, S., Wang, Y., Lei, X., Huang, D., Peng, L., Li, Z. and Xu, S., 2021. The impact of programmed death-ligand 1 expression on the prognosis of early stage resected non-small cell lung cancer: a meta-analysis of literatures. *Frontiers in Oncology*, 11, p.567978.
- Sohini, G. Tanya, M. and Stephanie, B. Editor MacRosty, C.R. and Rivera, M.P. eds., 2023. Staging and Diagnosis of Lung Cancer in *Lung Cancer: A Comprehensive Guide for the Clinician*. Springer Nature.
- Sugianto, G.C.K., 2019. Hubungan Antara Kadar Carcinoembryonic Antigen dan Cytokeratin-19 Fragments 21-1 dengan Kesintasan Satu Tahun Non-Small Cell Lung Carcinoma Stadium Lanjut Di RSUPN Dr. Cipto Mangunkusumo. The Association of Carcinoembryonic Antigen and Cytokeratin-19 Fragments 21-1 Levels with One-Year Survival of Advanced Non-Small Cell Lung Carcinoma at Dr. Cipto Mangunkusumo General Hospital.
- Tamasi, L., Horvath, K., Kiss, Z., Bogos, K., Ostoros, G., Müller, V., Urbán, L., Bittner, N., Sárosi, V., Vastag, A. and Polányi, Z., 2021. Age and gender

- specific lung cancer incidence and mortality in Hungary: trends from 2011 through 2016. *Pathology and Oncology Research*, 27, p.598862.
- Tcherkassova, J., Tsurkan, S., Prostyakova, A., Klinski, E., Sekacheva, M., Boroda, A., Moro, R. and Berz, D., 2023. A novel three-biomarker signature (CA-62, CEA, CYFRA 21-1) and early-stage NSC lung cancer detection.
- Visser, E., Genet, S.A., de Kock, R.P., van den Borne, B.E., Youssef-El Soud, M., Belderbos, H.N., Stege, G., de Saegher, M.E., Van't Westeinde, S.C., Brunsveld, L. and Broeren, M.A., 2023. Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. *Lung Cancer*, 178, pp.28-36.
- Wang, J., Linxweiler, M., Yang, W., Chan, T.A. and Morris, L.G., 2019. Immunomodulatory and immunotherapeutic implications of tobacco smoking in squamous cell carcinomas and normal airway epithelium. *Oncotarget*, 10(39), p.3835.
- Werner, S., Keller, L. and Pantel, K., 2020. Epithelial keratins: Biology and implications as diagnostic markers for liquid biopsies. *Molecular aspects of medicine*, 72, p.100817.
- Wolf, A.M., Oeffinger, K.C., Shih, T.Y.C., Walter, L.C., Church, T.R., Fontham, E.T., Elkin, E.B., Etzioni, R.D., Guerra, C.E., Perkins, R.B. and Kondo, K.K., 2023. Screening for lung cancer: 2023 guideline update from the American Cancer Society. *CA: A Cancer Journal for Clinicians*.
- Yatabe, Y., 2024. Molecular pathology of non-small cell carcinoma. *Histopathology*, 84(1), pp. 50-66.
- Yoon, S., Lim, Y.K., Kim, H.R., Lee, M.K. and Kweon, O.J., 2023. Establishment of Reference Intervals of Cytokeratin 19 Fragment Antigen 21-1 in Korean Adults. *Annals of laboratory medicine*, 43(1), pp.82-85.
- Zhao, W., Ren, W., Huang, D., Sang, Y., Cao, L. and Huang, J., 2022. Cell structure and physiology. In *Cell Movement in Health and Disease* (pp. 3-16). Academic Press.
- Zhou, Y., Qian, M., Li, J., Ruan, L., Wang, Y., Cai, C., Gu, S. and Zhao, X., 2024. The role of tumor-associated macrophages in lung cancer: From mechanism to small molecule therapy. *Biomedicine & Pharmacotherapy*, 170, p.116014.